Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation
Our understanding of Alzheimer’s disease (AD) pathophysiology remains incomplete. Here we used quantitative mass spectrometry
and coexpression network analysis to conduct the largest proteomic study thus far on AD. A protein network module
linked to sugar metabolism emerged as one of the modules most significantly associated with AD pathology and cognitive
impairment. This module was enriched in AD genetic risk factors and in microglia and astrocyte protein markers associated
with an anti-inflammatory state, suggesting that the biological functions it represents serve a protective role in AD. Proteins
from this module were elevated in cerebrospinal fluid in early stages of the disease. In this study of >2,000 brains and nearly
400 cerebrospinal fluid samples by quantitative proteomics, we identify proteins and biological processes in AD brains that
may serve as therapeutic targets and fluid biomarkers for the disease.
Published: August 17, 2023
Citation
Johnson E., E.B. Dammer, D.M. Duong, L. Ping, M. Zhou, Y. Yin, and L.A. Higginbotham, et al. 2020.Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation.Nature Medicine 26, no. 5:769–780.PNNL-SA-156646.doi:10.1038/s41591-020-0815-6